Form 4: Exagen Director Ana Hooker Granted 9,000 Stock Options

Exagen Inc. Director Ana Hooker was granted 9,000 stock options with an exercise price of $7.36, vesting on the first anniversary of the grant date or the next annual meeting.

Summary

• Ana Hooker, a Director of Exagen Inc. (XGN), was granted 9,000 stock options.
• The options have an exercise price of $7.36 per share.
• The grant date for these options was June 10, 2025.
• The options will become fully vested and exercisable on the earlier of June 10, 2026 (first anniversary of the grant date) or the date of the next annual meeting of Exagen's stockholders.
• Vesting is contingent upon Ms. Hooker's continued service on the board of directors.
• The options expire on June 9, 2035.
• Following this transaction, Ana Hooker beneficially owns 9,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns the director's interests with shareholders and serves as an incentive for long-term performance. It's a standard compensation practice.

Positives

• The grant of stock options aligns the director's interests with those of shareholders by providing an incentive for the company's stock price appreciation.
• The options have a long expiration date (June 9, 2035), providing ample time for potential value realization.

Negatives

• No direct negatives are apparent from a routine stock option grant.

Risks

• The value of the stock options is dependent on the future market price of Exagen Inc. common stock, which may not exceed the exercise price of $7.36.
• Vesting of the options is subject to the reporting person's continued service on the board of directors, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The vesting schedule indicates that the options will become exercisable on the first anniversary of the grant date or the next annual meeting, subject to continued service, providing a future incentive for the director.

Management Comments

• No direct quotes from management are provided in this Form 4 filing, which is typical for this document type.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, a common practice across various industries to align management and board interests with shareholder value creation. Such grants are standard in the biotechnology and diagnostics sector, where companies often use equity to attract and retain talent.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of non-cash compensation in publicly traded companies, particularly in the life sciences sector.
• The specific number of options (9,000) and the exercise price ($7.36) would need to be compared against similar grants at peer companies like Guardant Health (GH), Natera (NTRA), or Veracyte (VCYT) to assess if it's within typical ranges for a director of a company of Exagen's size and stage. Without specific peer data, it's difficult to make a direct quantitative comparison, but the mechanism itself is standard.

Related Party Transactions

• The grant of stock options to Ana Hooker, a Director of Exagen Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholders, potentially leading to better long-term performance and value creation.

Next Steps

• The stock options will vest on the first anniversary of the grant date (June 10, 2026) or the next annual meeting of stockholders, whichever occurs first.
• The reporting person must continue service on the board of directors for the options to vest.

Key Dates

Keywords

Exagen Inc., XGN, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Ana Hooker